As India’s fertility market becomes more regulated and patient expectations evolve, Jindal IVF is strengthening its clinical infrastructure, workforce training, and allied services to offer outcome-driven, ethical care at scale. Dr Umesh Jindal, Director & Senior Consultant, shares how the institution balances growth with quality – through strategic partnerships, rigorous lab protocols, and a full-spectrum reproductive health model.
- Jindal IVF has delivered over 12,000 babies since 1996. How do you plan to scale this volume further without compromising your high success rates? What revenue growth or patient volume increase are you targeting over the next five years?
At Jindal IVF, our focus is not on becoming a chain but on deepening our identity as a centre of excellence, which we have carefully built over the years and are committed to preserving. We are expanding thoughtfully through strategic partnerships with quality medical institutions across the region, along with a select number of our own centres that strictly adhere to our clinical and ethical benchmarks.
Growth will be driven by ensuring that every extension of our services maintains the same standard of care, lab infrastructure and success rates we are known for. Our goal is to make high-quality reproductive care more accessible without compromising on outcomes or patient trust.
- After the ART and surrogacy Laws were introduced in 2021. How does this accreditation translate into competitive advantage when pitching to corporate or Government healthcare buyers? What ROI have you observed in investing in advanced Laboratory capabilities?
In a domain where outcomes and accountability define institutional choices, Government accredited lab gives us the credibility to align with the expectations of corporate and government healthcare ecosystems. We are also accredited with NABH for Reproductive Medicine and Clinical Genetics in addition to other hospital facilities. These accreditations reflect a level of quality control and scientific discipline that resonates strongly with stakeholders looking for partners who can deliver consistent, ethical and high-success fertility interventions.
The ability to offer complex procedures like PGT and cryopreservation within a rigorously governed environment positions us as not just a service provider but a clinical thought leader. We have seen tangible returns in the form of greater trust from insurers, partners and patients. Beyond clinical metrics, the investment in lab excellence has enabled us to build systems that scale responsibly, where precision, data transparency and patient safety are deeply embedded into every protocol and partnership.
- With 140 staff and formal fellowship programmes in ART, how do you measure the impact of your training initiatives on clinical outcomes and staff retention? How can other clinics replicate your workforce‑development model?
Structured learning environments within our ecosystem are deeply tied to patient care, not peripheral to it. Through formal fellowships in ART and continuous on-site mentoring, we’ve cultivated a talent pipeline that not only meets clinical standards but pushes them higher. Impact is measured across multiple dimensions, from quality of embryo culture to improved procedural consistency, which in turn reflect in outcome stability.
Staff who train internally tend to stay longer, align better with our values and exhibit higher accountability in patient care. The replicability of this model lies in its seamless blend of classroom training, live clinical exposure and protocol-driven evaluation. Rather than treating training as a discrete module, we embed it into our culture of clinical excellence. Clinics seeking to adopt this approach need to commit to long-term learning ecosystems that prioritize mentorship, encourage audit-based improvements and treat every clinical case as an opportunity for team-wide growth.
- Jindal IVF now offers fertility preservation, Genetic counseling and pediatric NICU care. Which of these verticals has shown the fastest revenue growth or client demand, and how are you integrating them into your core IVF proposition?
Fertility preservation has emerged as the fastest-growing vertical in terms of both demand and strategic value, driven by rising awareness among younger individuals delaying parenthood for personal or medical reasons. Its growth has been particularly notable among oncology patients, professionals opting for egg or sperm freezing and couples exploring proactive reproductive planning. What sets this apart is how seamlessly it complements our IVF services, creating a continuum that spans preservation to parenthood.
Genetic counseling has further strengthened decision-making for patients undergoing ART or PGT, enhancing confidence in outcomes and treatment personalization. Many couples who have lost their pregnancies or children earlier benefit from Genetic diagnosis and counseling. Meanwhile, paediatric NICU care ensures that high-risk or premature births receive seamless postnatal support within the same ecosystem. Integrating these services under one umbrella allows us to offer a cohesive care model that not only attracts discerning patients but also builds loyalty through lifecycle support, reinforcing our positioning as a full-spectrum reproductive health institution.
- With the NMC Act mandating family‑medicine CME, is there scope for similar regulation or accreditation for fertility specialists? What policy changes would most improve quality standards and patient access in India’s IVF sector?
The evolving regulatory environment around continuous medical education opens an important conversation about formalizing similar requirements for fertility specialists. Given the pace at which reproductive medicine is advancing, structured CME could ensure clinicians stay updated on technologies like time-lapse embryo imaging, genetic screening and evolving stimulation protocols. A mandated CME framework, along with accreditation tied to outcomes and ethical standards, could significantly raise the clinical bar across India’s fragmented IVF sector.
Policy changes that would move the needle include expanding insurance or government-backed subsidies for ART, especially for lower-income families, and mandating outcome transparency among clinics. Uniform guidelines for consent, counselling and embryo handling would also address current gaps in standardization. Encouraging the development of regional ART registries and tighter lab audit protocols could further bridge disparities in access and quality. Aligning medical education policy with reproductive health would bring greater accountability and trust across the IVF care ecosystem.
